English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어
doc_reiner's profile picture. Medical Oncologist

Reiner John Villafuerte

@doc_reiner

Medical Oncologist

5Posts 17Followers 81Following
You might like
Reiner John Villafuerte reposted
JCO_ASCO's profile picture.
Journal of Clinical Oncology
@JCO_ASCO
Jun 10, 2020

Acalabrutinib versus investigator's choice therapy in chronic lymphocytic leukemia - the ASCEND trial fal.cn/38xA8 #CLL #leusm #JCO

JCO_ASCO's tweet image. Acalabrutinib versus investigator's choice therapy in chronic lymphocytic leukemia - the ASCEND trial fal.cn/38xA8 #CLL #leusm #JCO
0
7
8
1
0
Reiner John Villafuerte reposted
NEJM's profile picture.
NEJM
@NEJM
Jun 3, 2020

In this double-blind, randomized trial, 821 asymptomatic persons with a high- or moderate-risk exposure to #SARSCoV2 were assigned to receive hydroxychloroquine or placebo within 4 days after the exposure. No benefit in preventing illness compatible with #COVID19 was found.

55
1K
2K
62
0
Reiner John Villafuerte reposted
JCO_ASCO's profile picture.
Journal of Clinical Oncology
@JCO_ASCO
Jun 1, 2020

ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated #NSCLC fal.cn/38oWV #ASCODailyNews #LBA #ASCO20 @DrRoyHerbstYale @dave6408

JCO_ASCO's tweet image. ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated #NSCLC fal.cn/38oWV #ASCODailyNews #LBA #ASCO20 @DrRoyHerbstYale @dave6408
0
13
29
3
0
Reiner John Villafuerte reposted
DrRoyHerbstYale's profile picture.
Roy Herbst
 @DrRoyHerbstYale
May 31, 2020

Presenting the ADAURA data now @ASCO @ASCOPost at the plenary session. #ASCO20 The primary endpoint was met with DFS HR=0.17! Thank you to all the coinvestigators, study team & patients for participating in this practice changing study! @AstraZeneca @YaleCancer @Yale @LungMAP

DrRoyHerbstYale's tweet image. Presenting the ADAURA data now @ASCO @ASCOPost at the plenary session. #ASCO20 The primary endpoint was met with DFS HR=0.17! Thank you to all the coinvestigators, study team & patients for participating in this practice changing study! @AstraZeneca @YaleCancer @Yale @LungMAP
DrRoyHerbstYale's tweet image. Presenting the ADAURA data now @ASCO @ASCOPost at the plenary session. #ASCO20 The primary endpoint was met with DFS HR=0.17! Thank you to all the coinvestigators, study team & patients for participating in this practice changing study! @AstraZeneca @YaleCancer @Yale @LungMAP
DrRoyHerbstYale's tweet image. Presenting the ADAURA data now @ASCO @ASCOPost at the plenary session. #ASCO20 The primary endpoint was met with DFS HR=0.17! Thank you to all the coinvestigators, study team & patients for participating in this practice changing study! @AstraZeneca @YaleCancer @Yale @LungMAP
DrRoyHerbstYale's tweet image. Presenting the ADAURA data now @ASCO @ASCOPost at the plenary session. #ASCO20 The primary endpoint was met with DFS HR=0.17! Thank you to all the coinvestigators, study team & patients for participating in this practice changing study! @AstraZeneca @YaleCancer @Yale @LungMAP
9
95
247
17
0

United States Trends

You might like

Something went wrong.


Something went wrong.